OTCM
GENSY
Market cap1.95bUSD
Oct 20, Last price
28.38USD
Name
Genus PLC
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Genus plc is a global animal genetics company, with operations extending across North America, Latin America, the United Kingdom, broader Europe, the Middle East, Russia, Africa, and Asia. The firm organizes its business into three primary segments: Genus PIC, Genus ABS, and Genus Research and Development. Through its PIC brand, the company supplies breeding pigs and boar semen, enabling the production of swine with specific traits for pork processing. Furthermore, under the ABS, Genus, and Bovec labels, it provides bull semen and bovine embryos to facilitate the breeding of calves with targeted characteristics for dairy and beef output. Genus plc also extends specialized technical support to agricultural producers. Established in 1994, the company's headquarters are located in Basingstoke, United Kingdom.
Key people
Andy Russell
Chief Financial Officer, Executive Director · since 2025
Matt Culbertson
Chief Operating Officer · since 2023
Angelle Rosata
Chief Human Resources Officer · since 2023
Elena Rice
Chief Scientific Officer and Head of Research and Development · since 2019
Chief Executive Officer, Executive Director · since 2023
Jim Low
Chief Operating Officer of Genus ABS · since 2024
Jerry Thompson
Regional Director - ABS EMEA · since 2024
Non-Executive Director · since 2025
Robert Reiter
Non-Executive Director · since 2026
Non-Executive Independent Chairman of the Board · since 2020
Lysanne Gray
Non-Executive Independent Director · since 2016
Ralph Heuser
Non-Executive Independent Director · since 2024
Senior Non-Executive Independent Director · since 2018
Headquarters & legal address
MATRIX HOUSE
BASING VIEW
BASINGSTOKE, HAM RG21 4FF
GB
BASING VIEW
BASINGSTOKE, HAM RG21 4FF
GB
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑06 | 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||